

or more chloride channels from the group consisting of ClC-1, ClC-2, ClC-Ka, ClC-Kb, ClC-3, ClC-4, ClC-5, ClC-6 and ClC-7.

27. (New) A cell line according to Claim 26, which expresses the chloride channel ClC-7, but not the chloride channels ClC-3, ClC-4, ClC-5 and ClC-6.
28. (New) A cell line according to Claim 26, which expresses the chloride channel ClC-3, but not the chloride channels ClC-4, ClC-5, ClC-6, and ClC-7.
29. (New) A cell line according to Claim 26, which expresses the chloride channel ClC-4, but not the chloride channels ClC-3, ClC-5, ClC-6 and ClC-7.
30. (New) A cell line according to Claim 26, which expresses the chloride channel ClC-6, but not the chloride channels ClC-3, ClC-4, ClC-5 and ClC-7.
31. (New) The use of a genetically modified, non-human mammal, the germ cells and somatic cells of which contain nucleic acid sequences which code for a protein from the group consisting of the chloride channels ClC-1, ClC-2, ClC-Ka, ClC-Kb, ClC-3, ClC-4, ClC-5, ClC-6 and/or ClC-7, wherein the nucleic acid sequences coding for ClC-7 if present is modified with respect to the naturally occurring nucleic acid sequence by mutation, truncation, and/or partial deletion to result in a decreased or abolished functional expression of ClC-7, for the identification and testing of substances which are suitable for inhibiting one or more of the chloride channels.
32. (New) The use of a cell line according to Claim 27, for the identification and testing of substances which are suitable for inhibiting the chloride channel ClC-7.
33. (New) The use according to Claim 32, for the identification and testing of active compounds for treatment of osteoporosis or Paget's disease.
34. (New) The use of a cell line according to Claim 28, for the identification and testing of substances which are suitable for inhibiting the chloride channel ClC-3.
35. (New) The use of a cell line according to Claim 29, for the identification and testing of substances which are suitable for inhibiting the chloride channel ClC-4.

36. (New) The use of a cell line according to Claim 30, for the identification and testing of substances which are suitable for inhibiting the chloride channel ClC-6.
37. (New) The use according to Claim 32 or any one of Claims 34 to 36, for the identification and testing of active compounds which are suitable as psychotropic pharmaceuticals.
38. (New) A process for the identification and testing of substances which are suitable for inhibiting one or more chloride channels from the group consisting of ClC-3, ClC-4, ClC-5, ClC-6 and/or ClC-7, in which:
- a) on cells according to any one of Claims 26 to 30, the luminal pH of the compartments which express the channel and/or the potential across the membrane enclosing the channel is measured,
 - b) the cells are brought into contact with a substance and
 - c) the luminal pH of the compartments which express the channel and/or the potential across the membrane enclosing the channel is measured again on the cells,
- the difference between the pH and/or the membrane potential before and after addition of the substance determining the activity of the substance.
39. (New) A process according to Claim 38, wherein the pH is measured by accumulation of substances in compartments with a particular pH or detection of indicator substances which are formed in pH-dependent reactions in the compartments.
40. (New) A process according to Claim 38, wherein the potential is measured using potential-sensitive dyestuffs or protein-coded potential sensors.
41. (New) The use of substances which completely or partly inhibit the chloride channel ClC-7 for the preparation, of medicaments for treatment of osteoporosis and Paget's disease.